Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Activity Tracking Watch · 1 trial · 1 indication
The number of participants that wear the watch for at least 19.2 hours per day (80% of the time) will be reported.
The number of watches and data storage devices provisioned and returned free from malfunction will be reported.
The number of watches and data storage devices that successfully transmit data to central database will be reported.
The average daily overall activity will be reported.
The number of average daily total steps will be reported.
The average daily time spent in nonsedentary activity will be reported.
The average daily time spent in moderate-to-vigorous physical activity will be reported.
| Arm | Type | Description |
|---|---|---|
| Watch Wearing to Track Activity | EXPERIMENTAL | Participants wear a watch that tracks physical activity throughout study. |
| Name | Type | Description |
|---|---|---|
| Activity Tracking Watch | DEVICE | Device includes a wristwatch that tracks physical activity and a data storage unit that transmits data to a central database. |
Inclusion Criteria: The key inclusion criteria include but are not limited to: * Is in good health * Is willing to comply with study restrictions Exclusion Criteria: The key exclusion criteria include but are not limited to: * History of clinically significant endocrine, GI, cardiovascular, hem...
Activity Tracking Watch is an investigational device being studied in healthy volunteers. It is being developed by Merck & Company, Inc. (MRK). The device is currently in Phase 1 clinical development, with one completed trial involving 12 participants in the United States.
Activity Tracking Watch is being studied for use in healthy individuals. The completed Phase 1 trial, NCT06833879, enrolled 12 healthy volunteers aged 40 years and older. The study was conducted in the United States and was not randomized or blinded.
Activity Tracking Watch is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker MRK. The device is currently in Phase 1 clinical development.
Activity Tracking Watch is in Phase 1 clinical development. One trial, NCT06833879, has been completed. The study enrolled 12 healthy volunteers and was conducted in the United States. The device is investigational and not yet approved for any use.
Activity Tracking Watch has one completed clinical trial, NCT06833879, titled 'Activity Tracking Study in Healthy Volunteers (MK-0000-419)'. This Phase 1 study enrolled 12 healthy volunteers aged 40 years and older in the United States. The trial was uncontrolled and not randomized.